Anopirin

Quick links to important sections

Anopirin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anopirin

What is Anopirin?

Anopirin is a medication that belongs to a group of drugs known as antiplatelet agents. Its primary active ingredient is acetylsalicylic acid, which is used in low doses to influence how blood cells interact with one another.

Mechanism of Action

The medication works by inhibiting the aggregation of platelets, which are small cell fragments in the blood responsible for clotting. By reducing the ability of these platelets to stick together, Anopirin helps to maintain smoother blood flow through the arteries and veins.

Primary Purpose

In clinical practice, Anopirin is primarily used for the long-term management of cardiovascular health. Its role is centered on the prevention of blood clot formation (thrombosis), which can otherwise lead to serious vascular complications. It is often utilized by individuals who have a known risk of circulatory issues or those who have previously experienced cardiovascular events.

Characteristics

  • Active Substance: Acetylsalicylic acid.
  • Therapeutic Group: Antithrombotic and antiplatelet agent.
  • Formulation: Typically available as tablets designed for oral administration, often in lower strengths than those used for pain relief or fever reduction.

Regulatory References

  1. World Health Organization's Model List of Essential Medicines

What side effects are possible with Anopirin?

Adverse reaction scope

Serious and Clinically Significant Adverse Reactions

The most serious documented adverse reactions for Anopirin (Acetylsalicylic acid) primarily involve bleeding events and severe gastrointestinal (GI) toxicity. Serious bleeding risks include intracranial haemorrhage and severe gastrointestinal haemorrhage, ulceration, and perforation, which can be fatal. Other serious adverse events include severe hypersensitivity reactions such as anaphylactic shock and angio-oedema, as well as severe dermatological reactions like Stevens-Johnson syndrome.

Adverse Reaction Categories

Adverse reactions are classified by system-organ class, with the most common being Gastrointestinal disorders (e.g., dyspepsia, nausea, vomiting, and minor bleeding) and Blood and lymphatic system disorders (e.g., increased bleeding tendency).

  • Frequency Classification: Common adverse reactions include increased bleeding tendencies and general GI upset. Rare but serious events include thrombocytopenia, intracranial haemorrhage, and Reye's syndrome. The risk of bleeding may persist for 4–8 days following discontinuation due to the drug’s prolonged antiplatelet effect.

Population-Specific Safety Considerations

  • Children and Adolescents: Anopirin is contraindicated in children and adolescents recovering from viral infections (such as flu or chickenpox) due to the association with Reye's syndrome, a rare but severe illness involving liver and brain damage.
  • Elderly: This population faces an increased risk of severe GI toxicity (ulceration, bleeding, perforation).
  • Contraindications/Limitations: The medicine is restricted or contraindicated in patients with active pathological bleeding, severe hepatic or renal impairment, or a history of GI ulceration or haemorrhage. Caution is required when used concomitantly with other anticoagulants or before surgical procedures, including dental work.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Anopirin (Acetylsalicylic acid/Aspirin) results in a serious condition known as salicylate poisoning, which can occur after a single large ingestion or due to chronic exposure.

Documented Manifestations and Severe Outcomes

Regulatory documentation describes a range of symptoms and systemic effects. Early, milder manifestations (salicylism) include tinnitus (ringing in the ears), hearing impairment, nausea, vomiting, sweating, and hyperventilation. Severe intoxication is associated with central nervous system effects such as confusion, seizures, or coma, and serious outcomes like metabolic acidosis, acute renal failure, and cardiovascular collapse.

Mandatory Emergency Actions

Immediate medical attention is required for any suspected overdose or if severe symptoms are present. All patients must contact a Poison Control Center immediately and proceed to an emergency department. Hospital monitoring is necessary for a minimum of 24 hours, as symptoms and peak plasma levels may be delayed. There is no specific antidote for salicylate poisoning.

Management focuses on correcting fluid, electrolyte, and acid-base disturbances, and procedures like gastric lavage, activated charcoal administration, and alkaline diuresis may be required as supportive measures. For the most severe cases, hemodialysis may be necessary.

Therapeutic Uses of Anopirin

What Anopirin Treats: Main Uses and Benefits

The therapeutic uses of Anopirin encompass both symptomatic relief and preventative care in specific high-risk populations, supporting the management of various distressing symptoms and contributing to long-term protection.

Anopirin is commonly used when short-term symptomatic assistance is needed to address symptoms related to physical discomfort, such as headache, toothache, and cyclical menstrual pain. It also helps manage symptom clusters involving fever and generalized body aches associated with acute episodes. The medication is relevant across domains where additional symptomatic support is needed, including chronic conditions like rheumatoid arthritis and osteoarthritis, and is relevant in the secondary prevention of events like myocardial infarction (heart attack) and ischemic stroke.

“A major therapeutic purpose is easing the burden of symptoms that interfere with daily comfort, while also contributing to long-term vascular support.”

This application assists with maintaining functional stability by easing the burden of long-term inflammatory manifestations, and its preventative role contributes to long-term cardioprotection.


Quick Fact: Managing Acute Pain and Fever

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Anopirin

Populations for whom use is contraindicated

Use of Anopirin is absolutely prohibited for patients with known hypersensitivity to Acetylsalicylic acid (ASA) or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). It is also contraindicated in individuals with active peptic ulcer disease, a history of gastrointestinal bleeding, or established bleeding disorders. Regulatory documents prohibit use in patients with severe hepatic, renal, or cardiac insufficiency and in those with the syndrome of asthma, rhinitis, and nasal polyps.

Age-Related Eligibility Rules

Anopirin is contraindicated for children and teenagers who have or are recovering from viral illnesses, such as chickenpox or flu-like symptoms, due to the documented risk of Reye's syndrome. Older adults require cautious use due to a documented higher susceptibility to severe adverse reactions, particularly gastrointestinal bleeding.

Pregnancy and Lactation Eligibility Status

Use is not recommended or contraindicated during the third trimester of pregnancy. Regulatory guidance advises against NSAID use after 20 weeks gestation unless specifically directed by a physician. Low-dose ASA may be permitted for specific maternal medical conditions under specialized supervision. Regular use or high doses are generally discouraged while breastfeeding.

Eligibility-Related Restrictions

Use requires special caution in patients with a history of asthma, gout, uncontrolled hypertension, or mild-to-moderate organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Anopirin’s interaction profile, as defined by official regulatory documentation, is structured around documented pharmacokinetic (PK) and pharmacodynamic (PD) patterns that necessitate specific administration constraints and prohibitions.

Interaction Classification (Regulatory) Interacting Substances/Classes Constraint / Restriction
Formal Contraindications Methotrexate (>15 mg/week), Cidofovir, Ketorolac Strictly prohibited co-administration.
High-Risk Pharmacodynamic Oral Anticoagulants, Other NSAIDs, Alcohol Substantially increased risk of bleeding and gastrointestinal (GI) ulceration (additive effect).
PK/Clearance Interference Methotrexate, Valproic Acid, Uricosuric Agents Increased plasma exposure of Methotrexate (via reduced renal clearance); Altered serum levels of Valproic Acid (via protein displacement); Diminished effect of Uricosuric Agents.

Mandatory Administration Rules: A timing separation rule is officially required when co-administering Anopirin with Ibuprofen to prevent a pharmacodynamic interference with the antiplatelet action. Antacids should not be ingested simultaneously with gastro-resistant forms to avoid premature release. Co-administration with Mifepristone also requires a documented period of separation.

Population Notes: Regulatory labels advise that use is avoided/not recommended in cases of severe hepatic or renal impairment due to the potential for altered clearance and increased risk profile. These restrictions define the formal limits of co-administration as stated in prescribing information.

Mechanism of Action

Anopirin is a selective non-steroidal compound that primarily functions through the inhibition of the cyclooxygenase-2 (COX-2) enzyme. This interaction occurs at the enzyme's active site, resulting in a measurable decrease in the catalytic conversion of arachidonic acid. This inhibition directly leads to a reduced synthesis and local concentration of pro-inflammatory prostaglandins, including PGE2 and PGD2. This alteration in eicosanoid levels initiates the subsequent step of the mechanistic cascade: the attenuation of local inflammatory signaling. The lower concentration of prostaglandins in the cellular microenvironment modulates the activity of downstream signaling pathways. Specifically, this action is linked to a reduction in the release of inflammatory mediators that promote the proliferation and activity of osteoclasts. The resulting physiological modulation is localized to the inflammatory processes within musculoskeletal tissue, thereby altering the underlying biochemical environment without producing a therapeutic claim.

Dosage and Administration Information

How Anopirin is Used

Anopirin (Acetylsalicylic acid or ASA) usage is characterized by two primary protocols, based on the dose administered and the duration of use. The medicine is primarily administered via the oral route, though rectal suppositories are recognized for use when oral intake is constrained. Established parameters specify the conditions and frequency of administration.


Administration Guidelines

Usage Regimen Dose Range and Frequency Administration Constraint
Long-Term Preventative 75 mg to 162.5 mg once daily. Therapy is typically continued indefinitely for cardiovascular risk reduction.
Short-Term Analgesic 300 mg to 650 mg per dose, every 4 to 6 hours as needed. Do not exceed 4 g (4000 mg) in a 24-hour period; limit self-treatment to 10 days for pain.

Procedural and Age-Specific Rules

Standard instructions dictate specific administration procedures for different formulations. Delayed-release and extended-release tablets must be swallowed whole with a full glass of water and must not be cut, crushed, or chewed to preserve their intended release characteristics. The medicine may be taken with or after food to minimize gastrointestinal discomfort. For the short-term analgesic regimen, a minimum interval of 4 hours must be maintained between doses.

Guidance includes specific constraints for age-based administration: Anopirin is not generally recommended for children and adolescents under 16 years, unless specifically instructed by a healthcare provider. If a daily dose is missed, patients are instructed to skip the missed dose if closer to the next scheduled time, and not take a double dose to compensate.

Recent Clinical Evidence

Recent Clinical Evidence

Compound A for Acute Pain Management

Research has explored whether Compound A (the active ingredient in Anopirin) could influence acute pain. Several Randomized Controlled Trials (RCTs) investigated whether the compound could influence symptoms and influence relief for acute pain. The primary endpoint for many studies was the reduction in the Numeric Pain Rating Scale (NPRS) score within the first four hours of administration.

  • In general, findings suggested an effect greater than that observed with a placebo. The decision to consider any treatment change must be made in consultation with a healthcare professional.
  • One large meta-analysis compared outcomes with older pain treatments.
  • The treatment regimen used in one study involved administration every 6 hours.

Combined Therapy (Compound A + Adjuvant B)

The combination of Compound A with Adjuvant B was a focus of recent Phase III trials. Research has explored whether this combination influences pain severity over time, with secondary endpoints including mobility and sleep quality.

  • In trials, researchers examined whether the compound influenced inflammation.
  • Individuals with pre-existing kidney conditions were generally excluded from these specific studies.
  • Secondary analysis suggested that patients receiving the combination experienced an improvement in reported sleep quality compared to those receiving Compound A alone.

Safety and Tolerability Profile

Safety Profile: The trials included safety monitoring protocols for adult patients. The most commonly reported side effects in the included studies were gastrointestinal distress and headache.

  • Adverse effects reported were frequently classified as mild, and evidence regarding dependence was not reported in the findings of these trials.
  • The frequency of serious adverse events was observed to be low and comparable to that of the placebo group across most of the reviewed studies.

Key Studies & References

  1. Acute Pain Management: Scientific Evidence (5th Edition)
  2. Optimizing Acute Pain Management in Patients with Chronic Pain - CU School of Medicine (Review of meta-analyses and RCTs)
  3. The Safety Profile of Inclisiran in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis (Contains general methods for safety and AE assessment in RCTs)

Frequently Asked Questions (FAQ)

Common questions about Anopirin (FAQ)

Q: What is the main reason doctors prescribe Anopirin?

Official documents describe two main areas of approved use for Anopirin. It is used as an analgesic and anti-inflammatory agent to relieve pain and reduce fever. In a different regimen, it is also prescribed as an antiplatelet agent for specific preventative purposes related to blood clotting.


Q: How long after starting Anopirin do most people notice a difference?

Studies and official information indicate that for the relief of acute pain, the medicine can influence symptoms within approximately four hours. When taken for long-term preventative use, the antiplatelet effect begins quickly, but consistent, continuous administration is necessary to achieve the intended sustained benefit.


Q: Are there any common foods or drinks to avoid while taking Anopirin?

Official regulatory documentation highlights that the co-administration of alcohol is linked to a substantially increased risk of bleeding in the stomach or intestines. The official product information does not list any other common foods or non-alcoholic drinks as formal restrictions.


Q: How does Anopirin interact with commonly used over-the-counter medicines?

The official documentation describes known interactions with other pain relievers in the same drug class (NSAIDs, such as Ibuprofen), which requires a separation of dosing times. It also notes that antacids should not be taken at the same time as the gastro-resistant form. Information on all other specific over-the-counter compounds is not always listed in the core documents.


Q: Is Anopirin considered a high-risk medication?

Regulatory safety profiles highlight the potential for specific, serious adverse events, including severe bleeding and gastrointestinal toxicity. These risks are described in detail in official warnings, which are a required part of the medication’s labeling.


Q: What is the research status of Anopirin for new potential uses?

Official regulatory sources restrict information only to the uses for which the medicine has been formally approved. These documents do not typically contain information regarding the research status of new, unapproved, or potential uses that are outside the scope of the original authorization.


Q: What ingredients are in Anopirin besides the active drug?

Anopirin is a single-ingredient product containing the active substance, Acetylsalicylic acid. The tablet also includes pharmaceutical excipients, which are inactive substances used to help stabilize the medicine, aid in its manufacture, and ensure proper delivery of the active drug.


Q: Can Anopirin be taken on an empty stomach?

Official regulatory guidance states that the medicine may be taken with or after food to help minimize the potential for gastrointestinal discomfort. The guidance does not prohibit taking the medication without food.


Q: Is the information on Anopirin consistent across different regulatory bodies (FDA, EMA, etc.)?

Due to the compound's long-established scientific profile, the core information is substantially consistent across major global regulatory bodies, including the FDA, EMA, and WHO. This consistency applies to the active ingredient, its mechanism of action, and major safety contraindications.


Q: Is Anopirin the same kind of medication as [similar drug name]?

Anopirin is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) that also has a unique, irreversible antiplatelet action (affecting blood clotting). While other medications may belong to the same NSAID class, they may have different specific mechanisms, chemical structures, or approved uses.


Q: I heard Anopirin is used for [minor condition]. Is that true?

Official regulatory documents restrict the approved indications to relief of pain, inflammation, and use as an antiplatelet agent for specific preventative purposes. The documents do not formally authorize use for minor or unapproved conditions.


Q: Is it normal to feel [vague side effect] when first starting Anopirin?

Regulatory documents categorize adverse effects by how often they occurred in clinical trials. Effects such as headache and gastrointestinal distress are described as common. Official documents do not typically provide an expected timeline for when these effects may begin after starting the medication.


Q: What does 'contraindicated' mean in relation to Anopirin?

Contraindication is a term used in regulatory documents to signify a situation or specific condition where the use of a medication is strictly prohibited. In these cases, the risk to the patient is judged to significantly outweigh any potential benefit from the medicine.


Q: What is the risk of stopping Anopirin suddenly?

Official labeling for the long-term preventative regimen notes that the antiplatelet effect can persist for four to eight days following discontinuation. Regulatory documents describe the consequences as a loss of the therapeutic benefit, rather than detailing specific withdrawal symptoms.


Q: How is Anopirin different from a vitamin or supplement?

Anopirin is classified as a regulated medicine, specifically a synthetic chemical compound and a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its status defines it as having a specific, established pharmacological action on the body that is distinct from the function of a dietary vitamin or supplement.


Q: Can Anopirin affect the results of lab tests?

Regulatory documents include details on potential interference with certain laboratory assays. This may include tests related to blood glucose, uric acid, and thyroid function. The degree of potential interference is described as being related to the amount of medicine administered.


Q: Is Anopirin known to cause weight changes?

Official regulatory safety profiles for Anopirin do not list weight change among the commonly or rarely reported adverse reactions documented in clinical studies.


Q: What is the typical time frame for the effects of one dose of Anopirin to wear off?

The duration of the analgesic (pain-relieving) and fever-reducing effects of a single dose typically lasts for approximately four to six hours. This time frame aligns with the prescribed dosing interval for the medicine's short-term use.


Q: Does Anopirin cause tiredness or affect alertness?

Official safety profiles document potential central nervous system (CNS) effects such as headache and, rarely, dizziness. Significant drowsiness or general tiredness is not listed among the commonly reported adverse reactions for Anopirin.


Q: Do any official warnings mention driving while taking Anopirin?

Official prescribing information advises caution regarding operating machinery or driving only if a patient experiences certain adverse effects. This advisory is typically issued when side effects such as dizziness or vision disturbance, which have been documented in safety studies, occur.


Q: Does Anopirin have any known major interactions with herbal supplements?

Regulatory labels primarily focus on interactions with prescribed and over-the-counter medicines. Official documentation generally notes the lack of specific regulatory testing or documentation concerning herbal supplements.


Q: If I am taking Anopirin, do I need to avoid sun exposure?

Photosensitivity (an increased sensitivity to sunlight) or other reactions requiring the avoidance of sun exposure are not listed among the common or serious adverse reactions documented in the official regulatory safety profile for Anopirin.


Q: Is Anopirin a controlled substance?

Anopirin (Acetylsalicylic acid) is classified by regulatory authorities as either a scheduled prescription medicine or an over-the-counter medicine, depending on the dose and region. It is not classified as a controlled substance.


Q: Is Anopirin available without a prescription in some countries?

Anopirin is widely available without a prescription in many regions for its short-term use in pain and fever reduction, particularly in lower dose ranges. Higher doses or the long-term preventative regimen usually require a formal prescription.


Q: Are there any major diet restrictions associated with Anopirin?

Official regulatory documents list alcohol as a high-risk interaction but do not document any other major, formal dietary restrictions that must be followed while taking the medication.


Q: Does Anopirin affect blood pressure?

The official label notes that caution is required in patients with uncontrolled high blood pressure. Some medicines in the NSAID class are associated with fluid retention and a potential for small increases in blood pressure, which is a general warning documented within the class labeling.


Q: How long does Anopirin stay in your system?

The active analgesic compound clears relatively quickly from the bloodstream. However, the unique, irreversible antiplatelet effect of the medication can persist for four to eight days, as it lasts for the lifetime of the affected platelets.

How should Anopirin be stored and disposed of?

How to Store and Dispose of Anopirin

Official regulatory guidelines strictly define the conditions necessary to maintain the quality and integrity of Anopirin. Adherence to these requirements is mandatory.

Requirement Type Official Regulatory Statement
Storage Temperature Store at a specified temperature range, typically below 25 C (room temperature).
Environmental Protection Keep protected from moisture and direct light. Do not freeze.
Packaging Rules Must remain in the original, tightly closed container and carton until immediately before use.
Child Safety Keep this medicine out of the sight and reach of children.
Disposal Instructions Do not dispose of unused or expired medicine in household trash or via wastewater. Return product to a pharmacy or an authorized collection point for proper disposal in accordance with pharmaceutical waste regulations.

These official statements ensure the product remains stable until its expiry date and guide safe disposal to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anopirin found in:

A-Z Index: